NASDAQ-GS · traded in Congress
Cytokinetics, CYTK
$54.00 +0.31 (+0.58%) Nov 9, 2026 4:00 AM ET
Market value$7.5B
P/E ratio-
Analyst target$105.00
52-week range-
Avg volume1,901,461
Dividend yieldN/A
Chart
Analyst ratings
- 21 buy
- 2 hold
- 0 sell
Low target$78.00
Average target$109.42
High target$146.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $48M | - | $-190M | -399.7% | |
| $29M | - | $-199M | -694.4% | |
| $19M | - | $-206M | -1,064.5% | |
| $18M | - | $-183M | -1,030.9% |
New SEC filings
- 144 144 filed Nov 9, 2026
All CYTK filings on SEC EDGAR ›
Congress trades in CYTK
Members of Congress disclosed 2 transactions in CYTK in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 09/29/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 10/12/2026 filing |
| 06/30/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 7/2/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
